Ascendis Pharma is applying its innovative technology platform to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patientsâ lives. The company utilizes its TransCon technology with clinically validated parent drugs to create new therapies with potential for best-in-class efficacy, safety and/or convenience. Ascendis Pharma has a pipeline of three independent, rare disease endocrinology product candidates in clinical development, and has established oncology as its second therapeutic area of focus. Source
No articles found.
Addus HomeCare is a comprehensive provider of home and community based services, w...
Addus HomeCare is a comprehensive provider of h...
Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing...
Axsome Therapeutics, Inc. is a clinical-stage b...
Tiziana Life Sciences is a dual-listed (NASDAQ:TLSA, AIM:TILS) clinical stage biot...
Tiziana Life Sciences is a dual-listed (NASDAQ:...
We are a biopharmaceutical company focused on developing our pipeline featuring sp...
We are a biopharmaceutical company focused on d...
Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering,...
Gossamer Bio is a clinical-stage biopharmaceuti...
Phio Pharmaceuticals is focused on developing the next generation of immuno-oncolo...
Phio Pharmaceuticals is focused on developing t...
Crinetics is a clinical stage pharmaceutical company focused on the discovery, dev...
Crinetics is a clinical stage pharmaceutical co...
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the d...
Viking Therapeutics is a clinical-stage biophar...
Millendo Therapeutics is a late-stage biopharmaceutical company primarily focused ...
Millendo Therapeutics is a late-stage biopharma...
We are a late-stage biopharmaceutical company dedicated to bringing transformative...
We are a late-stage biopharmaceutical company d...
Join the National Investor Network and get the latest information with your interests in mind.